Nexalin Technology, Inc. NXL

NXL Company Overview

Nexalin Technology, Inc. is a U.S.-based medical technology company focused on non-invasive neurostimulation technologies intended to address mental health and neurological conditions. The company operates within the medical device and digital health industries, with a primary emphasis on therapies targeting anxiety, insomnia, depression, substance use disorders, and related behavioral health conditions. Its core commercial offering is the Gen-2 Neurostimulation Device, which uses low-frequency electrical stimulation designed to influence brainwave activity without pharmaceuticals or invasive procedures.

The company’s business model centers on device sales, treatment sessions, clinical expansion initiatives, and intellectual property development related to neurostimulation therapy. Nexalin has positioned itself within the growing neurotechnology and mental health treatment market by promoting non-drug therapeutic alternatives for patients and healthcare providers. Public filings and company disclosures indicate that the business evolved from earlier technology and healthcare ventures before focusing primarily on neurostimulation-based medical technologies. Data regarding certain early-stage historical corporate transitions is limited across public sources and partially inconsistent in secondary reporting.